Added to YB: 2026-02-17
Pitch date: 2026-02-15
PSNL [bullish]
Personalis, Inc.
+5.19%
current return
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
Market Cap
$761.1M
Pitch Price
$8.47
Price Target
14.57 (+64%)
Dividend
N/A
EV/EBITDA
-10.37
P/E
-9.79
EV/Sales
9.44
Sector
Life Sciences Tools and Services
Category
growth
The Small-Cap Biotech Reinventing Cancer Monitoring (PSNL)
PSNL: Ultra-deep MRD platform tracking thousands of personalized tumor variants to detect cancer relapse earlier. Medicare reimbursement secured for lung & breast cancer. Q3 clinical volumes +364% YoY. Partnerships w/ Moderna, Merck (16.5% stake), Tempus AI. $150M cash, ~18-24mo runway. Risk-weighted target $14.57 vs $8.21 current = ~77% upside. Risks: reimbursement expansion timing, adoption pace, competition from Natera/Guardant.
Read full article (6 min)